September 26-28, 2024
Cambridge, MA
#GlobalCMTResearchConvention
The CMT Research Foundation unites the voices of patients, researchers, pharma companies, and regulatory agencies to develop treatments for CMT.
This event takes place over three days. Thursday and Friday are scientific meetings meant for researchers and scientists working in CMT. Saturday is primarily for patients and their families and caregivers, providing a chance to interact with the research community that is working so hard on their behalf and to better understand the latest in research progress.
For the Scientific Community
September 26-27th
Two days for researchers, industry and government agencies to:
SHARE the latest in CMT drug development research
CREATE new connections and collaborations
EXAMINE the most pressing issues facing CMT drug development
Click here to see the full agenda
Agenda
Click here to see the full day of event agenda
Chris Austin, MD, PhD
CEO-Partner of Flagship Pioneering,
Chief Executive Officer of Vesalius Therapeutics and
Founding Director of the National Center for Advancing Translational Sciences (NCATS)
Are you interested in presenting a poster?
Submit your abstract here.
Vera Fridman
University of Colorado
Rudolf Martini
University of Würzbug
Rachel Bailey
University of Texas Southwestern Medical Center
For the Patient Community
September 28th
A day for the patient community to:
LEARN about the latest developments and clinical trials in CMT
INTERACT with distinguished scientific experts and clinicians
ACT to speed treatments for patients and families
Click here to see the full agenda
Agenda
Click here to see the full day of event agenda
Reza Seyedsadjadi, MD
Director, Charcot-Marie-Tooth (CMT) Center of Excellence, Massachusetts General Hospital
Assistant Professor of Neurology, Harvard Medical School
David Herrmann, MBBCh
Director, Charcot-Marie-Tooth (CMT) Center of Excellence, University of Rochester
Professor Department of Neurology, University of Rochester
Jim Lupski
Baylor College of Medicine
Katie Moss
Thomas Pedersen
NMD Pharma
Book your stay at the Royal Sonesta Boston with our special room rate here.
Past Sponsors
The Scientific Programming Committee
Charles Abrams, MD, PhD Chair
Professor of Neurology and Rehabilitation
University of Illinois, Chicago (UIC)
Tiina Urv, PhD
Program Director, Office of Rare Diseases Research
U.S. National Center for Advancing Translational Sciences (NCATS)
Paul August, PhD
Chief Scientific Officer
ReviR Therapeutics
Glen Nuckolls, PhD
Program Director, Neurogenetics, Division of Neuroscience
U.S. National Institute of Neurological Disorders and Stroke (NINDS)
Amanda Haidet-Phillips, PhD
Executive Director, Global Program Team Leader
Sarepta Therapeutics
Afrooz Rashnonejad, MSc, PhD
Principal Investigator, Center for Gene Therapy, Abigail Wexner Research Institute
Nationwide Children’s Hospital
If you have any questions please contact Vanessa Sanchez at
[email protected] or +1 (404) 474-8805